SCHEMBL5380336

SCHEMBL5380336

COc1ccc(Nc2n[nH]c(SCc3cc(C)on3)n2)cc1OC

nearest known ligand 0.69

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 17/20 0.69
EPHA2 P29317 1/20 0.40
KDR P35968 1/20 0.40
ENPP1 P22413 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376819 0.88 METAP2 (0.68) METAP2KDR
SCHEMBL5385578 0.85 METAP2 (0.65) METAP2
SCHEMBL5372134 0.84 METAP2 (0.53) METAP2
SCHEMBL5376879 0.83 METAP2 (0.67) METAP2
SCHEMBL5371852 0.83 METAP2 (0.55) METAP2
SCHEMBL5376459 0.82 METAP2 (0.53) METAP2
SCHEMBL5376716 0.82 METAP2 (0.53) METAP2
SCHEMBL5376431 0.82 METAP2 (0.70) METAP2
SCHEMBL5381128 0.82 METAP2 (0.69) METAP2EPHA2KDR
SCHEMBL5376528 0.81 METAP2 (0.70) METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304082-B2 1,2,4-triazole derivatives, compositions, process of making and methods of use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-04 US disclosed
US-20050267185-A1 1,2,4-triazole derivatives, compositions, process of making and methods of use SMITHKLINE BEECHAM CORPORATION 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267185-A1 1,2,4-triazole derivatives, compositions, process of making and methods of use METAP2, METAP1, DNPEP METAP2 1/4885EPHA2 1636/4885KDR 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.